相似文献
1
Reply to Chen, A.; Zhang, X. Comment on "Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. 2023, , 4081".
Cancers (Basel). 2023 Nov 28;15(23):5619. doi: 10.3390/cancers15235619.
2
Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. 2023, , 4081.
Cancers (Basel). 2023 Nov 28;15(23):5618. doi: 10.3390/cancers15235618.
3
Gastrointestinal Stromal Tumours of the Rectum - Evaluating the National Registry Data with Respect to its Use in Clinical Practice.
Klin Onkol. 2019 Spring;32(2):117-123.
4
Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
Cancers (Basel). 2023 Aug 13;15(16):4081. doi: 10.3390/cancers15164081.
5
The radiology of gastrointestinal stromal tumours (GIST).
Cancer Imaging. 2005 Dec 15;5(1):150-6. doi: 10.1102/1470-7330.2005.0109.
6
Retraction Statement: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats.
J Neurochem. 2017 May;141(3):473-474. doi: 10.1111/jnc.13949. Epub 2017 Mar 6.
7
Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on "Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. 2023, , 553".
J Pers Med. 2023 Jun 13;13(6):988. doi: 10.3390/jpm13060988.
8
Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it.
World J Gastroenterol. 2013 Apr 28;19(16):2583-6. doi: 10.3748/wjg.v19.i16.2583.
9
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Drugs. 2003;63(5):513-22; discussion 523-4. doi: 10.2165/00003495-200363050-00005.
10
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Gastric Cancer. 2023 May;26(3):339-351. doi: 10.1007/s10120-023-01381-6. Epub 2023 Mar 13.
引用本文的文献
1
Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.
Int J Mol Sci. 2024 Jan 12;25(2):945. doi: 10.3390/ijms25020945.
2
Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. 2023, , 4081.
Cancers (Basel). 2023 Nov 28;15(23):5618. doi: 10.3390/cancers15235618.
本文引用的文献
1
Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. 2023, , 4081.
Cancers (Basel). 2023 Nov 28;15(23):5618. doi: 10.3390/cancers15235618.
2
Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors - a real-world multi-center study.
Transl Oncol. 2023 Apr;30:101641. doi: 10.1016/j.tranon.2023.101641. Epub 2023 Feb 13.
3
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.
Target Oncol. 2022 Nov;17(6):627-634. doi: 10.1007/s11523-022-00926-6. Epub 2022 Nov 14.
4
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors.
Front Oncol. 2022 Aug 31;12:927587. doi: 10.3389/fonc.2022.927587. eCollection 2022.
5
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21.
6
Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital.
J Oncol Pharm Pract. 2022 Jun;28(4):822-826. doi: 10.1177/10781552211008212. Epub 2021 Apr 12.
7
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018.
8
Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study.
Oncotarget. 2017 Apr 3;8(41):71128-71137. doi: 10.18632/oncotarget.16795. eCollection 2017 Sep 19.
9
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Oncotarget. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136.
10
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.
Zotero 插件